Swisher Daniel N JR sold $111K of CORT

Swisher Daniel N JR sold 1,500 shares of CORCEPT THERAPEUTICS INC (CORT) at $74.07 ($0.11M total) on 2026-11-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Swisher Daniel N JR
Published Nov 13, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
medium confidence
Mentioned
$CORT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

A director's complete exit may be interpreted as a lack of confidence, potentially prompting short sellers.

02

Market read

The filing provides new, material information about insider ownership, but the monetary size is modest, limiting broader market impact.

03

What to watch

The director may have needed liquidity; the sale price was close to market.

Relevance 3/10Novelty 3/10Timing: after-hours filing

Background

SEC Form 4 filings disclose insider transactions; they are primary sources for such events.

Company-level read

Ticker impact

$CORTBearishMedium confidence
Context

Director Swisher Daniel N Jr sold 1,500 shares for $111,105 via a 10b5-1 plan, reducing his holding to zero.

Expected impact

likely modest downside as market prices in the insider sell

Evidence & confidence

A director offloading a sizable position, even at a modest $111K, often prompts short-term selling pressure.

Market effects

Minimal impact on the biotech sector; insider sales are company‑specific.

None

None

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Corcept Therapeutics Inc.

    Biopharma company listed on NASDAQ under ticker CORT.

  • Swisher Daniel N Jr

    Director of Corcept Therapeutics who sold his shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.